ReviewOncogene2005
Viruses - seeking and destroying the tumor program.
Review in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.Journal of cellular and molecular medicine · 2020Article
- Viral hijacking of cellular metabolism.BMC biology · 2019Review
- Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.Cancer discovery · 2018Article
- Ki67 targeted strategies for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.Molecular therapy oncolytics · 2017Article
- Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.Journal of ovarian research · 2016Article
- Article
- Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication.Cell metabolism · 2014Article
- Article
- Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell.Cancer science · 2012Article
- Assessment of hazard risk associated with the intravenous use of viral vectors in rodents.Comparative medicine · 2012Article
- Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches.PLoS computational biology · 2012Article
- Epigenetic mechanisms in virus-induced tumorigenesis.Clinical epigenetics · 2011Article
- Increasing the efficacy of oncolytic adenovirus vectors.Viruses · 2010Article
- Cancer: Viruses' backup plan.Nature · 2010Article
- Article
- Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.Pediatric blood & cancer · 2010Article
- ODE models for oncolytic virus dynamics.Journal of theoretical biology · 2010Article
- Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.Cancer gene therapy · 2010Article
- Viral manipulation of DNA repair and cell cycle checkpoints.DNA repair · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.